StocksMedium•8 October 2026•
1 min read
FDA Grants AbbVie's Temab-A Two Breakthrough Therapy Designations
Key Facts
1The FDA granted AbbVie's Temab-A two Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.
The FDA granted AbbVie's Temab-A two Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer. Zacks reported that these designations are intended to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies for serious conditions.
ABBV closed at $271.36 on October 7, 2026, with the stock reaching a day high of $274.94 and a low of $266.89 during that session. This development supports the company's oncology pipeline, as FDA breakthrough designations typically accelerate drug approval timelines.